• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Third-line pharmacotherapy for type 2 diabetes erratum
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Case management for vulnerable or homeless persons: clinical and cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Diagnostic computed tomography angiography for adult patients: safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Nitroglycerin for the treatment of pulmonary edema following submersion: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Vitamin D testing for northern populations: clinical and cost-effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Long-term use of ranibizumab for the treatment of age-related macular degeneration: a review of the clinical and cost-effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Alcohol with chlorhexidine hand sanitizers: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin-resistant enterococci isolation and screening strategies: clinical evidence and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Mobile x-ray imaging versus fixed x-ray imaging in long-term care: clinical and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Ingenol mebutate (Picato - LEO Pharma Inc.) indication: actinic keratosis
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ingenol mebutate (Picato LEO Pharma Inc.) indication: topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ingenol mebutate (Picato LEO Pharma Inc.) indication: topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Plasma Vaporization of the Prostate for Treatment of Benign Prostatic Hypertrophy: A review of clinical and cost-effectiveness, and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography scanners for patients in rural or remote locations: clinical and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) The ABCD2 scoring system for transient ischemic attacks: a review of the diagnostic accuracy and predictive value
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Fall risk assessment in adult patients: comparative evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Endoscopic ultrasound for the diagnosis of disease and staging of cancers in adult patients with gastroenterological or oncological disease: guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Mobilization of adult inpatients in hospitals or long-term/chronic care facilities: benefits and harms, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Hepatitis C polymorphism testing: a review of the clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Platelet rich plasma lumbar disc injections for lower back pain: clinical effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: a review of clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Diabetes care for indigenous populations: a review of the clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Bolused (vice infused) tranexamic acid in adults experiencing hemorrhagic shock: safety, patient benefits, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Lyophilized plasma for the treatment of adults with hemorrhagic shock: clinical and cost-effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Suboxone versus methadone for the detoxification of patients addicted to prescription opioids: a review of comparative clinical effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) iTClamp for controlling compressible gemorrhage in adults: clinical effectiveness, cost-effectiveness, and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Nutritional supplementation for patients with cancer: a review of the clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Interventions for non-elderly patients who are high users of ambulatory and emergency medical services: clinical and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Non-invasive prenatal testing: a review of the cost effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Trientine for treatment of Wilson's disease: clinical and cost-effectiveness, and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Magnetic resonance spectroscopic imaging for prostate disease detection: clinical and cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Next generation DNA sequencing: a review of the cost effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Icatibant for patients with type III hereditary angioedema: a review of clinical effectiveness and harms
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Single-use medical devices reprocessed by third party/licenced reprocessors: patient benefits and harms, cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Drug interventions for chronic non-cancer pain: guidelines and recommendations
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Non-drug interventions for chronic non-cancer pain: guidelines and recommendations
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Flushing intravenous tubing post administration of medications: clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Paracentesis for the removal of peritoneal fluid: guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Positron emission tomography in neurology and cardiology: a review of guidelines and recommendations
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine/naloxone (Suboxone) film versus buprenorphine/naloxone tablets for the treatment of opioid addiction: comparative safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Compressible non-articulating disc prostheses in adult patients with degenerative disc disease: clinical effectiveness, safety, cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Smart infusion pump use in hospitalized patients: clinical safety and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Intranasal versus intravenous administration of anxiolytic or analgesic medications: comparative clinical effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Intensivist response time to a closed intensive care unit: patient benefits and harms and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) TECNIS® or Acrysof® soft intraocular lenses for patients undergoing cataract surgery: benefits and harms, clinical effectiveness, cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Wireless device use and patient monitoring equipment in any healthcare delivery setting: a review of safety and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Nicotine replacement therapy for smoking cessation or reduction: a review of the clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Dexmedetomidine for sedation of patients in the ICU or PICU: review of clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Subsequent entry biologics — emerging trends in regulatory and health technology assessment frameworks
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Goal setting tools for children: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Maxillary artery ligation for the treatment of cluster or migraine headaches: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Hemodialysis chairs versus beds for patients at out-patient clinics: clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography-guided brachytherapy treatment in the operating room: clinical effectiveness, cost-effectiveness, and guidelines
2014 Blue Cross Blue Shield Association (BCBS) Use of digital breast tomosynthesis with mammography for breast cancer screening or diagnosis
2014 Blue Cross Blue Shield Association (BCBS) Artificial lumbar disc arthroplasty
2014 Blue Cross Blue Shield Association (BCBS) CYP2D6 pharmacogenomics of tamoxifen treatment
2014 Blue Cross Blue Shield Association (BCBS) Transcranial magnetic stimulation for depression
2014 Blue Cross Blue Shield Association (BCBS) Percutaneous tibial nerve stimulation for the treatment of voiding dysfunction
2014 Blue Cross Blue Shield Association (BCBS) Gene expression analysis for prostate cancer management
2014 Blue Cross Blue Shield Association (BCBS) Myocardial sympathetic innervation imaging in heart failure
2014 Blue Cross Blue Shield Association (BCBS) Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine
2014 Blue Cross Blue Shield Association (BCBS) Artificial pancreas device systems
2014 Blue Cross Blue Shield Association (BCBS) Special report: screening asymptomatic women with dense breasts and normal mammograms for breast cancer
2014 NIHR Health Technology Assessment programme The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials
2014 NIHR Health Technology Assessment programme Coronary artery bypass grafting in high-RISk patients randomised to off- or on-Pump surgery: a randomised controlled trial (the CRISP trial)
2014 Health Council of the Netherlands Gezondheidsraad (GR) ADHD: medication and society
2014 Health Council of the Netherlands Gezondheidsraad (GR) Participation by young people with mental health problems
2014 NIHR Health Technology Assessment programme Changing eating behaviours to treat childhood obesity in the community using Mandolean: the Community Mandolean randomised controlled trial (ComMando) - a pilot study
2014 Health Council of the Netherlands Gezondheidsraad (GR) Population screening for breast cancer: expectations and developments
2014 Health Council of the Netherlands Gezondheidsraad (GR) Criteria for the selection of a vaccine against pertussis
2014 Health Council of the Netherlands Gezondheidsraad (GR) Fighting the flu
2014 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [How to improve the management of depression? A qualitative approach]
2014 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Neonatal screening for classic galactosemia. Systematic review]
2014 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Newborn screening for congenital adrenal hyperplasia. Systematic Review]
2014 HAYES, Inc. Ancillary procedures and services for the treatment of gender dysphoria